Skip to main content
. 2022 Jul 18;13:4157. doi: 10.1038/s41467-022-31642-4

Fig. 4. Crizotinib improves the efficiency of cell competition in HFD-fed mouse liver.

Fig. 4

a Timeline of the experimental procedure. C57BL/6 mice were fed ND or HFD for 3 months and subjected to HTVi with empty control or plasmid-encoding GFP-N-RasV12-IRES-luciferase (N-RasV12, n = 5 (ND), n = 4 (HFD); N-RasV12 + Crizotinib, n = 10 (ND), n = 11 (HFD)). Some HFD-fed mice were orally administered 50 mg/kg crizotinib thrice. The mice were euthanized and subjected to in vivo bioluminescent imaging to confirm the GFP-N-RasV12-IRES-luciferase expression at days 1 and 6. b The average body weight of each group on day 6 in (a) (N-RasV12, n = 5 (ND), n = 4 (HFD); N-RasV12 + Crizotinib, n = 10 (ND), n = 11 (HFD)). N-RasV12: HFD vs ND, P = 0.016, N-RasV12 + Crizotinib: HFD vs ND, P < 0.001. c Immunofluorescence analysis of liver sections stained using N-Ras (red) and cell nuclei stained using DAPI (blue). Scale bar, 20 μm. d The values of relative luminescence in each group (see “Methods”). The relative luminescence was normalized by the mice subjected to HTVi with empty control and ND-fed mice. HFD (N-RasV12) vs (ND) N-RasV12, P = 0.017; HFD (N-RasV12) vs HFD (N-RasV12 + Crizotinib), P = 0.013. *P < 0.05, ***P < 0.001, or not significant (N.S.) by Wilcoxon rank-sum test (b), or one-way ANOVA, followed by Tukey’s multiple comparisons posthoc test (d).